113 related articles for article (PubMed ID: 18533195)
1. The optimal dose of CAF regimen in adjuvant chemotherapy for breast cancer patients at stage IIB.
Khaloozadeh H; Yazdanbakhsh P; Homaei-shandiz F
Math Biosci; 2008 Jun; 213(2):151-8. PubMed ID: 18533195
[TBL] [Abstract][Full Text] [Related]
2. [Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst].
de Jong N; Kester AD; Schouten HC; Abu-Saad HH; Courtens AM
Pflege Z; 2007 Nov; 60(11):620-5. PubMed ID: 18062627
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of adriamycin for advanced breast cancer (3)--a joint study by 26 institutes on the CAF and CMcF treatment].
Kubo K; Abe O; Izuo M; Enomoto K; Koyama H; Sakai K; Terasawa T; Tominaga T; Nomura Y
Gan To Kagaku Ryoho; 1983 Dec; 10(12):2523-31. PubMed ID: 6689117
[TBL] [Abstract][Full Text] [Related]
4. [Feasibility of adjuvant high-dose CAF (cyclophosphamide, adriamycin, 5-FU) therapy for primary breast cancer patients].
Toi M; Hayashi K; Tominaga T
Gan To Kagaku Ryoho; 1994 Sep; 21(12):2057-60. PubMed ID: 8085859
[No Abstract] [Full Text] [Related]
5. [Treatment of advanced breast cancer with 2 successive chemotherapeutic schedules].
Pérez JE; Machiavelli M; Romero A; Leone BA; Rabinovich MG; Arévalo E
Medicina (B Aires); 1982; 42(6 Pt 1):587-95. PubMed ID: 6897849
[No Abstract] [Full Text] [Related]
6. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline-based adjuvant chemotherapy in breast cancer.
Montemurro F; Aglietta M
Lancet; 2010 May; 375(9729):1871; author reply 1871-2. PubMed ID: 20511012
[No Abstract] [Full Text] [Related]
8. [A case of breast cancer patient of CAF (cyclophosphamide, adriamycin, 5-fluorouracil) resistant lung metastasis with remarkable response to reverse drug-resistance by toremifene].
Kusama M; Kaise H; Nakayama S; Ohta D; Aoki T; Koyanagi Y
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1171-5. PubMed ID: 10431584
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G
J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727
[TBL] [Abstract][Full Text] [Related]
10. [Hemostimulating properties of cropanol during cytostatics-induced myelosuppression].
Zhdanov VV; Gol'dberg VE; Khrichkova TIu; Matiash MG; Gur'iantseva LA; Simolina EI; Vysotskaia VV; Suslov NI; Popova NO; Dygaĭ AM
Eksp Klin Farmakol; 2002; 65(6):37-40. PubMed ID: 12596531
[TBL] [Abstract][Full Text] [Related]
11. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Bustová I
Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
[TBL] [Abstract][Full Text] [Related]
12. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
Tonkin K; Bates M; Lieu D; Arundell E; Williamson T; Zagari M
Can J Oncol; 1996 Nov; 6(2):458-73. PubMed ID: 12056098
[TBL] [Abstract][Full Text] [Related]
13. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
Tamura K
Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
[No Abstract] [Full Text] [Related]
14. Muehrcke's lines on nails after cyclophosphamide/adriamycin/fluorouracil.
Gül U; Kiliç A
Ann Pharmacother; 2004 Jun; 38(6):1089-90. PubMed ID: 15122002
[No Abstract] [Full Text] [Related]
15. Influence of smoking history on breast cancer prognosis: retrospective study of 240 operable breast cancer patients who received adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil chemotherapy regimen.
Aksoy S; Harputluoglu H; Guler N; Altundag K; Hayran M; Tekuzman G; Ozisik Y
Breast J; 2007; 13(4):431-2. PubMed ID: 17593056
[No Abstract] [Full Text] [Related]
16. Dose density in breast cancer: a simple message?
Lin NU; Gelman R; Winer EP
J Natl Cancer Inst; 2005 Dec; 97(23):1712-4. PubMed ID: 16333021
[No Abstract] [Full Text] [Related]
17. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic outcomes of adjuvant chemotherapy in non-target cells of breast cancer patients.
Kopjar N; Milas I; Garaj-Vrhovac V; Gamulin M
Hum Exp Toxicol; 2007 May; 26(5):391-9. PubMed ID: 17623763
[TBL] [Abstract][Full Text] [Related]
19. Dose-dense chemotherapy for primary breast cancer.
Kümmel S; Rezai M; Kimmig R; Schmid P
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
[TBL] [Abstract][Full Text] [Related]
20. Start tamoxifen after completing chemotherapy, US researchers say.
McCarthy M
Lancet; 2002 Jun; 359(9321):1925. PubMed ID: 12057564
[No Abstract] [Full Text] [Related]
[Next] [New Search]
